On 7 May 2026, the EU reached a provisional agreement to push back the hardest deadlines in the EU AI Act. Many leadership teams heard one message: “we’ve got more time”. In this solo episode, Dr Andree Bates explains why that exhale is dangerous. The timeline moved, but the governance exposure did not.

Dr Andree breaks down what the delay does and does not change. The dates may shift, but the architecture of the AI Act remains intact: risk classification, documentation, oversight, robustness, logging, conformity assessment, and post market monitoring. These are not last minute checklist items. They are operational capabilities you have to build, test, and keep running.

The real risk, she argues, is misreading “more time” as permission to wait. The hardest work is operational: finding every AI system across the enterprise, including vendor embedded AI inside platforms like CRM and workflow tools, distinguishing genuine AI from marketing labels, classifying systems properly, assigning ownership, and building processes that still hold when vendors update models or features under the hood.

She also tackles a costly misconception for US based pharma: the EU AI Act is deliberately extraterritorial. Scope follows where outputs are used, not where the company is headquartered. If AI outputs touch EU employees, regulators, clinicians, or patients, you may be in scope, even if the system is built and operated in the US.

Dr Andree’s bottom line: the companies that treat this runway as time to build will compound governance maturity and deploy faster with less risk. The ones that wait will hit 2027 under compression, with more shadow AI, more remediation, and less credibility when scrutiny arrives.

Topics Covered

What moved in the EU AI Act timeline, and what did not
Why AI governance is an operating model, not a deadline project
The real work: inventory, classification, ownership, documentation
Vendor embedded AI and shadow AI as hidden exposure
High risk obligations and why you can’t assemble them late
Extraterritorial scope and why US pharma is still in scope
What to do with the runway: build maturity, not delay

Eularis helps pharma and biotech leaders turn AI activity into board-defensible strategy and measurable commercial outcomes.If your organisation has plenty of AI in motion but very little that moves the commercial needle in a way the board can see, start with our 10-Day AI Diagnostic Sprint. It’s a focused diagnostic that surfaces what’s actually broken and what’s blocking results, before you invest in a larger strategy effort.

The Sprint diagnoses the problem. The AI Strategic Blueprint that follows is where we build the board-defensible strategy and plan.Details at eularis.com.

If this episode described your situation, send me a LinkedIn DM starting with ‘SENSECHECK’ and two things: the question you’re trying to answer internally, and what’s currently in flight. I’ll reply with what I’d need to see to turn that activity into a defensible plan, and the next step.

About the Podcast

AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.

E221: The Diagnostic Room: The AI Governance Timeline Moved. Your Governance Exposure Didn't

AI For Pharma Growth

E221: The Diagnostic Room: The AI Governance Timeline Moved. Your Governance Exposure Didn't